基孔肯雅病毒的抗病毒前景
Antiviral perspectives for chikungunya virus.
作者信息
Parashar Deepti, Cherian Sarah
机构信息
National Institute of Virology, 20-A Dr. Ambedkar Road, Pune 411001, India.
出版信息
Biomed Res Int. 2014;2014:631642. doi: 10.1155/2014/631642. Epub 2014 May 15.
Abstract
Chikungunya virus (CHIKV) is a mosquito-borne pathogen that has a major health impact in humans and causes acute febrile illness in humans accompanied by joint pains and, in many cases, persistent arthralgia lasting for weeks to years. CHIKV reemerged in 2005-2006 in several parts of the Indian Ocean islands and India after a gap of 32 years, causing millions of cases. The re-emergence of CHIKV has also resulted in numerous outbreaks in several countries in the eastern hemisphere, with a threat to further expand in the near future. However, there is no vaccine against CHIKV infection licensed for human use, and therapy for CHIKV infection is still mainly limited to supportive care as antiviral agents are yet in different stages of testing or development. In this review we explore the different perspectives for chikungunya treatment and the effectiveness of these treatment regimens and discuss the scope for future directions.
摘要
基孔肯雅病毒（CHIKV）是一种通过蚊子传播的病原体，对人类健康有重大影响，可导致人类急性发热疾病，并伴有关节疼痛，在许多情况下还会出现持续数周甚至数年的持续性关节痛。在间隔32年后，CHIKV于2005 - 2006年在印度洋岛屿和印度的多个地区再次出现，导致数百万病例。CHIKV的再次出现还在东半球的几个国家引发了多次疫情，并在不久的将来有进一步蔓延的威胁。然而，目前尚无获得许可用于人类的抗CHIKV感染疫苗，并且由于抗病毒药物仍处于不同的测试或研发阶段，CHIKV感染的治疗仍主要限于支持性护理。在本综述中，我们探讨了基孔肯雅热治疗的不同观点以及这些治疗方案的有效性，并讨论了未来方向的范围。
相似文献
1
Antiviral perspectives for chikungunya virus.基孔肯雅病毒的抗病毒前景
Biomed Res Int. 2014;2014:631642. doi: 10.1155/2014/631642. Epub 2014 May 15.
2
Molecular epidemiology, evolution and phylogeny of Chikungunya virus: An updating review.基孔肯雅病毒的分子流行病学、进化与系统发育：一篇综述更新
Infect Genet Evol. 2016 Jul;41:270-278. doi: 10.1016/j.meegid.2016.04.006. Epub 2016 Apr 13.
3
Chikungunya: Its History in Africa and Asia and Its Spread to New Regions in 2013-2014.基孔肯雅热：其在非洲和亚洲的历史以及在2013 - 2014年向新地区的传播
J Infect Dis. 2016 Dec 15;214(suppl 5):S436-S440. doi: 10.1093/infdis/jiw391.
4
Chikungunya virus-vector interactions.基孔肯雅病毒与媒介的相互作用。
Viruses. 2014 Nov 24;6(11):4628-63. doi: 10.3390/v6114628.
5
Evaluation of chikungunya virus infection in children from India during 2009-2010: A cross sectional observational study.评估 2009-2010 年印度儿童的基孔肯雅病毒感染：一项横断面观察性研究。
J Med Virol. 2016 Jun;88(6):923-30. doi: 10.1002/jmv.24433. Epub 2015 Dec 15.
6
Reemergence of chikungunya virus.基孔肯雅病毒的再次出现。
J Virol. 2014 Oct;88(20):11644-7. doi: 10.1128/JVI.01432-14. Epub 2014 Jul 30.
7
Differential susceptibility & replication potential of Vero E6, BHK-21, RD, A-549, C6/36 cells & mosquitoes to three strains of chikungunya virus.三种基孔肯雅病毒株对vero E6、BHK-21、RD、A-549、C6/36 细胞及蚊子的易感性和复制潜能。
Indian J Med Res. 2019 Jun;149(6):771-777. doi: 10.4103/ijmr.IJMR_453_17.
8
A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development.基孔肯雅热病毒的流行病学、发病机制和当前疫苗开发研究进展综述。
Viruses. 2022 May 5;14(5):969. doi: 10.3390/v14050969.
9
Chikungunya Virus as Cause of Febrile Illness Outbreak, Chiapas, Mexico, 2014.2014年，基孔肯雅病毒引发墨西哥恰帕斯州发热疾病疫情
Emerg Infect Dis. 2015 Nov;21(11):2070-3. doi: 10.3201/eid2111.150546.
10
Cellular and molecular mechanisms of chikungunya pathogenesis.基孔肯雅热发病机制的细胞和分子机制。
Antiviral Res. 2015 Aug;120:165-74. doi: 10.1016/j.antiviral.2015.06.009. Epub 2015 Jun 16.
引用本文的文献
1
Antiviral Effect of Piperine on Chikungunya Virus: Evidence and Analysis of E1-E2 Binding.胡椒碱对基孔肯雅病毒的抗病毒作用：E1-E2结合的证据与分析
ACS Omega. 2025 Aug 6;10(32):35865-35877. doi: 10.1021/acsomega.5c02814. eCollection 2025 Aug 19.
2
Infectomics of Chikungunya Virus: Roles Played by Host Factors.基孔肯雅病毒的感染组学：宿主因素所起的作用
Am J Trop Med Hyg. 2024 Dec 17;112(3):481-490. doi: 10.4269/ajtmh.23-0819. Print 2025 Mar 5.
3
Chikungunya Virus and Its Envelope Protein E2 Induce Hyperalgesia in Mice: Inhibition by Anti-E2 Monoclonal Antibodies and by Targeting TRPV1.基孔肯雅病毒及其包膜蛋白 E2 诱导小鼠痛觉过敏：抗 E2 单克隆抗体和靶向 TRPV1 的抑制作用。
Cells. 2023 Feb 9;12(4):556. doi: 10.3390/cells12040556.
4
Growth in chikungunya virus-related research in ASEAN and South Asian countries from 1967 to 2022 following disease emergence: a bibliometric and graphical analysis.1967 年至 2022 年虫媒病毒相关研究在东盟和南亚国家的增长：文献计量和图形分析。
Global Health. 2023 Feb 6;19(1):9. doi: 10.1186/s12992-023-00906-z.
5
Targeted gene silencing of E2 and nsP1 genes of chikungunya virus by biocompatible zeolitic imidazolate framework.通过生物相容性沸石咪唑酯骨架对基孔肯雅病毒的E2和nsP1基因进行靶向基因沉默。
Front Bioeng Biotechnol. 2022 Dec 14;10:1003448. doi: 10.3389/fbioe.2022.1003448. eCollection 2022.
6
Development and Application of Treatment for Chikungunya Fever.基孔肯雅热治疗方法的研发与应用
Res Rep Trop Med. 2022 Dec 16;13:55-66. doi: 10.2147/RRTM.S370046. eCollection 2022.
7
An evaluation of global Chikungunya clinical management guidelines: A systematic review.全球基孔肯雅热临床管理指南评估：一项系统综述。
EClinicalMedicine. 2022 Sep 28;54:101672. doi: 10.1016/j.eclinm.2022.101672. eCollection 2022 Dec.
8
MBZM-N-IBT, a Novel Small Molecule, Restricts Chikungunya Virus Infection by Targeting nsP2 Protease Activity , , and .MBZM-N-IBT，一种新型小分子，通过靶向 nsP2 蛋白酶活性来限制基孔肯雅病毒感染。
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0046322. doi: 10.1128/aac.00463-22. Epub 2022 Jun 29.
9
In silico and in vitro evaluation of silibinin: a promising anti-Chikungunya agent.水飞蓟宾的计算机模拟和体外评估：一种有前景的抗基孔肯雅病毒药物。
In Vitro Cell Dev Biol Anim. 2022 Mar;58(3):255-267. doi: 10.1007/s11626-022-00666-x. Epub 2022 Apr 5.
10
Effect of Cationic Lipid Nanoparticle Loaded siRNA with Stearylamine against Chikungunya Virus.阳离子脂质纳米颗粒负载带有硬脂胺的 siRNA 对基孔肯雅病毒的作用。
Molecules. 2022 Feb 9;27(4):1170. doi: 10.3390/molecules27041170.
本文引用的文献
1
Effectiveness of chloroquine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikungunya virus infection.感染基孔肯雅病毒后早期持续性肌肉骨骼疼痛和关节炎患者中氯喹的疗效和炎症细胞因子反应。
Arthritis Rheumatol. 2014 Feb;66(2):319-26. doi: 10.1002/art.38221.
2
Approaches to the treatment of disease induced by chikungunya virus.基孔肯雅病毒所致疾病的治疗方法。
Indian J Med Res. 2013 Nov;138(5):762-5.
3
A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.一种新型基于痘病毒的疫苗，MVA-CHIKV，具有高度的免疫原性，可保护小鼠免受基孔肯雅热感染。
J Virol. 2014 Mar;88(6):3527-47. doi: 10.1128/JVI.03418-13. Epub 2014 Jan 8.
4
Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.基孔肯雅热候选疫苗高度减毒，可在单次接种后保护非人类灵长类动物免受遥测监测疾病的侵害。
J Infect Dis. 2014 Jun 15;209(12):1891-9. doi: 10.1093/infdis/jiu014. Epub 2014 Jan 7.
5
Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.新型减毒基孔肯雅病毒疫苗候选株在C57BL/6小鼠中引发保护性免疫。
J Virol. 2014 Mar;88(5):2858-66. doi: 10.1128/JVI.03453-13. Epub 2013 Dec 26.
6
Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library.通过高通量筛选激酶抑制剂文库鉴定新型化合物抑制基孔肯雅病毒诱导的细胞死亡。
PLoS Negl Trop Dis. 2013 Oct 31;7(10):e2471. doi: 10.1371/journal.pntd.0002471. eCollection 2013.
7
Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions.开发一种稳定的基孔肯雅病毒样颗粒疫苗制剂并研究多阴离子的作用。
J Pharm Sci. 2013 Dec;102(12):4305-14. doi: 10.1002/jps.23749. Epub 2013 Oct 15.
8
Chikungunya virus: emerging targets and new opportunities for medicinal chemistry.基孔肯雅热病毒：药物化学的新兴靶点和新机遇。
J Med Chem. 2014 Feb 27;57(4):1147-66. doi: 10.1021/jm400460d. Epub 2013 Oct 23.
9
Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus.给予 E2 和 NS1 siRNA 可抑制体外的基孔肯雅病毒复制，并保护感染该病毒的小鼠。
PLoS Negl Trop Dis. 2013 Sep 5;7(9):e2405. doi: 10.1371/journal.pntd.0002405. eCollection 2013.
10
Methotrexate treatment causes early onset of disease in a mouse model of Ross River virus-induced inflammatory disease through increased monocyte production.甲氨蝶呤治疗通过增加单核细胞生成导致罗斯河病毒诱导的炎症性疾病小鼠模型疾病的早期发作。
PLoS One. 2013 Aug 12;8(8):e71146. doi: 10.1371/journal.pone.0071146. eCollection 2013.
Zotero 插件